In recent years, albumin NCs have gained considerable research attention as a drug delivery system owing to the approval by the FDA of nanoparticle albumin-bound (NAB) paclitaxel (Abraxane®) in the treatment of metastatic breast cancer (2005), advanced/metastatic non-small cell lung cancer (2012), and metastatic pancreatic cancer (2013). The gene discussed is ALB; the disease is non-small cell lung carcinoma.